2013 Q3 Form 10-K Financial Statement

#000082787114000015 Filed on December 22, 2014

View on sec.gov

Income Statement

Concept 2013 Q3 2012 2011 Q3
Revenue $4.640M $2.539M
YoY Change 254.2% -73.27%
Cost Of Revenue $2.930M $3.166M
YoY Change 248.81% 75.89%
Gross Profit $1.710M -$627.0K
YoY Change 271.74% -108.14%
Gross Profit Margin 36.85% -24.69%
Selling, General & Admin $820.0K $6.399M
YoY Change -50.9% 39.11%
% of Gross Profit 47.95%
Research & Development $3.420M $12.81M
YoY Change 26.2% 47.18%
% of Gross Profit 200.0%
Depreciation & Amortization $20.00K $240.0K
YoY Change -60.0% -11.11%
% of Gross Profit 1.17%
Operating Expenses $4.240M $22.37M
YoY Change -3.42% 68.2%
Operating Profit -$2.530M -$19.83M
YoY Change -35.62% 254.13%
Interest Expense -$1.040M $91.00K
YoY Change 225.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$333.0K
YoY Change
Pretax Income $480.0K -$20.16M
YoY Change -111.19% 266.62%
Income Tax $0.00 -$781.0K
% Of Pretax Income 0.0%
Net Earnings $480.0K -$19.38M
YoY Change -111.16% 272.75%
Net Earnings / Revenue 10.34% -763.41%
Basic Earnings Per Share
Diluted Earnings Per Share $34.48K -$1.396M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2012 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.50M $6.600M
YoY Change -47.62%
Cash & Equivalents $10.46M $5.100M $8.100M
Short-Term Investments $0.00 $1.500M
Other Short-Term Assets $32.00K $600.0K
YoY Change -25.0%
Inventory $0.00 $100.0K
Prepaid Expenses
Receivables $5.124M $1.600M
Other Receivables $0.00 $0.00
Total Short-Term Assets $17.48M $8.900M
YoY Change -39.86%
LONG-TERM ASSETS
Property, Plant & Equipment $402.0K $500.0K
YoY Change -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $46.00K $100.0K
YoY Change 0.0%
Total Long-Term Assets $620.0K $500.0K
YoY Change -37.5%
TOTAL ASSETS
Total Short-Term Assets $17.48M $8.900M
Total Long-Term Assets $620.0K $500.0K
Total Assets $18.10M $9.400M
YoY Change -39.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.192M $1.400M
YoY Change -6.67%
Accrued Expenses $3.130M $1.300M
YoY Change -27.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $8.600M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.34M $20.90M
YoY Change 124.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.700M $700.0K
YoY Change
Total Long-Term Liabilities $1.700M $700.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.34M $20.90M
Total Long-Term Liabilities $1.700M $700.0K
Total Liabilities $16.00M $21.50M
YoY Change 131.18%
SHAREHOLDERS EQUITY
Retained Earnings -$102.1M
YoY Change
Common Stock $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$87.93M -$12.10M -$71.17M
YoY Change
Total Liabilities & Shareholders Equity $18.10M $9.400M
YoY Change -39.74%

Cashflow Statement

Concept 2013 Q3 2012 2011 Q3
OPERATING ACTIVITIES
Net Income $480.0K -$19.38M
YoY Change -111.16% 272.75%
Depreciation, Depletion And Amortization $20.00K $240.0K
YoY Change -60.0% -11.11%
Cash From Operating Activities -$320.0K -$15.55M
YoY Change -94.35% 57.69%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $33.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $3.000M
YoY Change -100.0% -166.67%
Cash From Investing Activities -$10.00K $2.967M
YoY Change -99.33% -165.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.00K $9.548M
YoY Change -100.21% -45.09%
NET CHANGE
Cash From Operating Activities -320.0K -$15.55M
Cash From Investing Activities -10.00K $2.967M
Cash From Financing Activities -20.00K $9.548M
Net Change In Cash -350.0K -$3.033M
YoY Change -114.4% -200.1%
FREE CASH FLOW
Cash From Operating Activities -$320.0K -$15.55M
Capital Expenditures -$10.00K $33.00K
Free Cash Flow -$310.0K -$15.58M
YoY Change -94.52% 58.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4059000 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1192000 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5124000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7296000 USD
CY2013Q3 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
0 USD
CY2014Q3 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
204000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9671000 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3130000 USD
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000 USD
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
275000 USD
CY2014Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
890000 USD
CY2013Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
170000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-780000 USD
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-822000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
137259000 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14204000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
655000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
0 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
402000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
317000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
606000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2074000 USD
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
606000 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
317000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
402000 USD
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1091000 USD
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
218000 USD
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
96000 USD
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
19000 USD
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7934060 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3871141 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8448711 shares
CY2013Q3 us-gaap Assets
Assets
18103000 USD
CY2014Q3 us-gaap Assets
Assets
53411000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
53022000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
17483000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22722000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10456000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5067000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8100000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5389000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3033000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12266000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
974311 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3048131 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14032167 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3048131 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14032167 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
14000 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2013 us-gaap Cost Of Revenue
CostOfRevenue
7381000 USD
CY2014 us-gaap Cost Of Revenue
CostOfRevenue
11714000 USD
CY2012 us-gaap Cost Of Revenue
CostOfRevenue
3166000 USD
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000 USD
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000 USD
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000 USD
CY2013 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
10062000 USD
CY2014 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2012 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2013Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
172000 USD
CY2014Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2013Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
47000 USD
CY2014Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
143000 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6585000 USD
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10020000 USD
CY2014Q3 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
80000 USD
CY2013Q3 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
28000 USD
CY2013Q3 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
208000 USD
CY2014Q3 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
234000 USD
CY2014Q3 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
34000 USD
CY2013Q3 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
39000 USD
CY2014Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38389000 USD
CY2013Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32817000 USD
CY2013Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2573000 USD
CY2014Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2354000 USD
CY2013Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
32770000 USD
CY2014Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
38246000 USD
CY2013Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26984000 USD
CY2014Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32527000 USD
CY2014Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2000 USD
CY2013Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2000 USD
CY2013Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
688000 USD
CY2014Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
944000 USD
CY2014Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
0 USD
CY2013Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
24000 USD
CY2014Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-38246000 USD
CY2013Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-32770000 USD
CY2014Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
70000 USD
CY2013Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
77000 USD
CY2014Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
138000 USD
CY2013Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
47000 USD
CY2012 us-gaap Depreciation
Depreciation
240000 USD
CY2014 us-gaap Depreciation
Depreciation
104000 USD
CY2013 us-gaap Depreciation
Depreciation
135000 USD
CY2013 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3837000 USD
CY2012 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3933000 USD
CY2014 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1666000 USD
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.25
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.11
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.1294
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0672
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0388
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.3400
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2511
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3465
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3225
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0006
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0022
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0007
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.1295
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0388
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0672
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0514
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0062
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0072
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2614000 USD
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1052000 USD
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
573000 USD
CY2013 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
4050000 USD
CY2014 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2012 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20164000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6947000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19272000 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-781000 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1295000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-899000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2867000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-93000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-251000 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3543000 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2172000 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1320000 USD
CY2014 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6692000 USD
CY2012 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-521000 USD
CY2013 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1694000 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3435000 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3500000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
520000 USD
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1294000 USD
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1052000 USD
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-87000 USD
CY2013 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-30000 USD
CY2012 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
CY2014 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000 USD
CY2014 us-gaap Interest Expense
InterestExpense
8000 USD
CY2013 us-gaap Interest Expense
InterestExpense
309000 USD
CY2012 us-gaap Interest Expense
InterestExpense
91000 USD
CY2014Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2014 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2012 us-gaap Interest Expense Debt
InterestExpenseDebt
109000 USD
CY2013 us-gaap Interest Expense Debt
InterestExpenseDebt
545000 USD
CY2013 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q3 us-gaap Interest Paid
InterestPaid
8000 USD
CY2012 us-gaap Interest Paid
InterestPaid
0 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
0 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
1294000 USD
CY2014Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1294000 USD
CY2013Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
0 USD
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 USD
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 USD
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
34000 USD
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
314000 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
329000 USD
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
277000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53411000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18103000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20315000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14342000 USD
CY2014 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2506000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9548000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46154000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9809000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2967000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20045000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1459000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9885000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23316000 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19643000 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-515000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-19831000 USD
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
445000 USD
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
68000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13843000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5879000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15548000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-6048000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-19383000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-17977000 USD
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-333000 USD
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1508000 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
37856000 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
22134000 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
22370000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-8455000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-18757000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
182000 USD
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
329000 USD
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
32000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35000 USD
CY2013 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2012 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2014 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
3765000 USD
CY2014 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2013 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
20000 USD
CY2012 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2012 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000 USD
CY2014 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1711000 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1903000 USD
CY2014Q3 us-gaap Prepaid Insurance
PrepaidInsurance
345000 USD
CY2013Q3 us-gaap Prepaid Insurance
PrepaidInsurance
118000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
6500000 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46069000 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46069000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
9829000 USD
CY2014 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2012 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2014 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
-19999000 USD
CY2013 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
1500000 USD
CY2012 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
3000000 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000 USD
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
19099000 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21000 USD
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21000 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21000 USD
CY2013Q3 us-gaap Professional Fees
ProfessionalFees
1993000 USD
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1124000 USD
CY2013Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1224000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
402000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
344000 USD
CY2014Q3 us-gaap Purchase Obligation
PurchaseObligation
2319000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9795000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12805000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16816000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104177000 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102136000 USD
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
10708000 USD
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
8364000 USD
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
1384000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5880000 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
179000 USD
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1845000 USD
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4626000 USD
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5315000 USD
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1155000 USD
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
2539000 USD
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
13679000 USD
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6399000 USD
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9326000 USD
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4958000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
317000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
402000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
606000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.3938
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.64
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.64
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.537
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.64
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.3434
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0216
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0323
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0253
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0177
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0082
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0095
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
113513 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
120614 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
50931 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
195471 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
558699 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
194065 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.73
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.61
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.40
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
813259 shares
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
657850 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
739808 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.16
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.32
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.58
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1308993 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.22
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
369245 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
435582 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
510656 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
596092 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.34
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.72
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.42
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.78
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
19999000 USD
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2014 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3450000 shares
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12034 shares
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46048000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
33096000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
-87929000 USD
CY2011Q3 us-gaap Stockholders Equity
StockholdersEquity
-71174000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
-93433000 USD
CY2013 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
3837000 USD
CY2014 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1666000 USD
CY2012 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
3933000 USD
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5476000 USD
CY2013Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1707000 USD
CY2014Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 USD
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9955937 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3044308 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1652904 shares
CY2013 egrx Accrued Ipo Costs
AccruedIPOCosts
152000 USD
CY2012 egrx Accrued Ipo Costs
AccruedIPOCosts
0 USD
CY2014 egrx Accrued Ipo Costs
AccruedIPOCosts
0 USD
CY2013Q3 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
63000 USD
CY2014Q3 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
490000 USD
CY2014Q3 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
1498000 USD
CY2013Q3 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
283000 USD
CY2013 egrx Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense
AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense
309000 USD
CY2014 egrx Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense
AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense
0 USD
CY2012 egrx Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense
AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense
90000 USD
CY2012Q1 egrx Asset Purchase Agreement Royalty On Net Profitsof Products Term
AssetPurchaseAgreementRoyaltyOnNetProfitsofProductsTerm
P10Y
CY2014Q3 egrx Assets Heldfor Future Use Not Subjectto Depreciation
AssetsHeldforFutureUseNotSubjecttoDepreciation
270000 USD
CY2013Q3 egrx Assets Heldfor Future Use Not Subjectto Depreciation
AssetsHeldforFutureUseNotSubjecttoDepreciation
270000 USD
CY2014 egrx Classof Warrantor Right Expected Term
ClassofWarrantorRightExpectedTerm
P6Y
CY2008Q2 egrx Collaborative Product Development Agreement Cumulative Milestones Upon Achievementof Goals
CollaborativeProductDevelopmentAgreementCumulativeMilestonesUponAchievementofGoals
13000000 USD
CY2008Q2 egrx Collaborative Product Development Agreement Monthly Receivable
CollaborativeProductDevelopmentAgreementMonthlyReceivable
200000 USD
CY2008Q2 egrx Collaborative Product Development Agreement Non Refundable Amount Receivedfor Signing
CollaborativeProductDevelopmentAgreementNonRefundableAmountReceivedforSigning
750000 USD
CY2008Q2 egrx Collaborative Product Development Agreement Paymentfor Product Development
CollaborativeProductDevelopmentAgreementPaymentforProductDevelopment
2000000 USD
CY2012 egrx Deferred Financingcosts
DeferredFinancingcosts
-115000 USD
CY2014 egrx Deferred Financingcosts
DeferredFinancingcosts
0 USD
CY2013 egrx Deferred Financingcosts
DeferredFinancingcosts
0 USD
CY2013 egrx Deferred Ipo Costs
DeferredIPOCosts
-20000 USD
CY2014 egrx Deferred Ipo Costs
DeferredIPOCosts
0 USD
CY2012 egrx Deferred Ipo Costs
DeferredIPOCosts
0 USD
CY2014Q3 egrx Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment
DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment
6000000 USD
CY2013Q3 egrx Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment
DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment
6000000 USD
CY2014Q3 egrx Deferred Tax Assets Accrued Vacation Pay
DeferredTaxAssetsAccruedVacationPay
54000 USD
CY2013Q3 egrx Deferred Tax Assets Accrued Vacation Pay
DeferredTaxAssetsAccruedVacationPay
0 USD
CY2014Q3 egrx Deferred Tax Assets Fixed Assets
DeferredTaxAssetsFixedAssets
0 USD
CY2013Q3 egrx Deferred Tax Assets Fixed Assets
DeferredTaxAssetsFixedAssets
161000 USD
CY2013Q3 egrx Deferred Tax Assets In Process Researchand Development Credit
DeferredTaxAssetsInProcessResearchandDevelopmentCredit
2033000 USD
CY2014Q3 egrx Deferred Tax Assets In Process Researchand Development Credit
DeferredTaxAssetsInProcessResearchandDevelopmentCredit
1886000 USD
CY2014Q3 egrx Deferred Tax Assets Operating Loss Carryforwards Domesticand Stateand Local
DeferredTaxAssetsOperatingLossCarryforwardsDomesticandStateandLocal
90448000 USD
CY2013Q3 egrx Deferred Tax Assets Operating Loss Carryforwards Domesticand Stateand Local
DeferredTaxAssetsOperatingLossCarryforwardsDomesticandStateandLocal
29881000 USD
CY2013Q3 egrx Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
0 USD
CY2014Q3 egrx Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
5000 USD
CY2014 egrx Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest
0.0107
CY2012 egrx Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest
0.0000
CY2013 egrx Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest
0.1382
CY2012Q1 egrx Expected Cash Proceeds Upon Regulatory Approval Milestone
ExpectedCashProceedsUponRegulatoryApprovalMilestone
1000000 USD
CY2014Q3 egrx Expected Cash Proceedson Additional Milestones Dependenton Licensor Sales Activity
ExpectedCashProceedsonAdditionalMilestonesDependentonLicensorSalesActivity
3000000 USD
CY2013 egrx Gain Losson Subscription Loan Settlement
GainLossonSubscriptionLoanSettlement
0 USD
CY2014 egrx Gain Losson Subscription Loan Settlement
GainLossonSubscriptionLoanSettlement
0 USD
CY2012 egrx Gain Losson Subscription Loan Settlement
GainLossonSubscriptionLoanSettlement
-51000 USD
CY2013 egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
20000 USD
CY2012 egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
20000 USD
CY2014 egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
9000 USD
CY2014 egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-192000 USD
CY2012 egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-197000 USD
CY2013 egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
1368000 USD
CY2014 egrx Lawsuit Invoked Regulatory Stayof Approval
LawsuitInvokedRegulatoryStayofApproval
P30M
CY2014 egrx Marketing Rights Term
MarketingRightsTerm
P10Y
CY2012Q1 egrx Milestonereductionfor Regulatory Approvalof Generic Competitor Minimum
MilestonereductionforRegulatoryApprovalofGenericCompetitorMinimum
500000 USD
CY2012 egrx Operating Loss Carryforwards Sales
OperatingLossCarryforwardsSales
10740000 USD
CY2013 egrx Operating Loss Carryforwards Sales
OperatingLossCarryforwardsSales
11029000 USD
CY2014 egrx Operating Loss Carryforwards Sales
OperatingLossCarryforwardsSales
25389000 USD
CY2014 egrx Orphan Drug Exclusivity Regulatory Agency Stayof Application Incremental Domestic Periodfor Pediatric Exclusivity
OrphanDrugExclusivityRegulatoryAgencyStayofApplicationIncrementalDomesticPeriodforPediatricExclusivity
P6M
CY2014 egrx Orphan Drug Exclusivity Regulatory Agency Stayof Application Maximum Period
OrphanDrugExclusivityRegulatoryAgencyStayofApplicationMaximumPeriod
P7Y
CY2014Q3 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
197000 USD
CY2013Q3 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1023000 USD
CY2013Q3 egrx Prepaid Product Costs
PrepaidProductCosts
730000 USD
CY2014Q3 egrx Prepaid Product Costs
PrepaidProductCosts
840000 USD
CY2014 egrx Proceedsfrom Issuanceof Convertible Notesand Warrants
ProceedsfromIssuanceofConvertibleNotesandWarrants
0 USD
CY2013 egrx Proceedsfrom Issuanceof Convertible Notesand Warrants
ProceedsfromIssuanceofConvertibleNotesandWarrants
0 USD
CY2012 egrx Proceedsfrom Issuanceof Convertible Notesand Warrants
ProceedsfromIssuanceofConvertibleNotesandWarrants
9663000 USD
CY2014 egrx Product Development Agreements Exclusive Rights Acquired Numberof Products
ProductDevelopmentAgreementsExclusiveRightsAcquiredNumberofProducts
33 product
CY2014 egrx Royalty Revenue Commercial Partners Obligationof Sales Report Term
RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm
P60D
CY2013 egrx Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Intrinsic Value
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedIntrinsicValue
0 USD
CY2014 egrx Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Intrinsic Value
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedIntrinsicValue
83000 USD
CY2011Q3 egrx Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber
288605 shares
CY2013Q3 egrx Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber
302603 shares
CY2014Q3 egrx Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber
712901 shares
CY2012Q3 egrx Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber
304226 shares
CY2014Q1 egrx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1788 shares
CY2014Q1 egrx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1788 shares
CY2014 egrx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
21000 USD
CY2013Q3 egrx Tax Credit Carryforward Federaland State Researchand Development
TaxCreditCarryforwardFederalandStateResearchandDevelopment
59000 USD
CY2014Q3 egrx Tax Credit Carryforward Federaland State Researchand Development
TaxCreditCarryforwardFederalandStateResearchandDevelopment
1827000 USD
CY2014 egrx Tax Credit Carryforwardsales
TaxCreditCarryforwardsales
177000 USD
CY2012 egrx Tax Credit Carryforwardsales
TaxCreditCarryforwardsales
11000 USD
CY2013 egrx Tax Credit Carryforwardsales
TaxCreditCarryforwardsales
95000 USD
CY2012Q3 egrx Temporary Equity Accumulated Accretionof Dividends
TemporaryEquityAccumulatedAccretionofDividends
15385000 USD
CY2014Q3 egrx Temporary Equity Accumulated Accretionof Dividends
TemporaryEquityAccumulatedAccretionofDividends
0 USD
CY2013Q3 egrx Temporary Equity Accumulated Accretionof Dividends
TemporaryEquityAccumulatedAccretionofDividends
15935000 USD
CY2014 egrx Warrants Issued During Period Value Warrants
WarrantsIssuedDuringPeriodValueWarrants
0 USD
CY2013 egrx Warrants Issued During Period Value Warrants
WarrantsIssuedDuringPeriodValueWarrants
0 USD
CY2012 egrx Warrants Issued During Period Value Warrants
WarrantsIssuedDuringPeriodValueWarrants
1309000 USD
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0000827871
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14032167 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q1 dei Entity Public Float
EntityPublicFloat
101476651 USD
CY2014 dei Entity Registrant Name
EntityRegistrantName
Eagle Pharmaceuticals, Inc.
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No

Files In Submission

Name View Source Status
0000827871-14-000015-index-headers.html Edgar Link pending
0000827871-14-000015-index.html Edgar Link pending
0000827871-14-000015.txt Edgar Link pending
0000827871-14-000015-xbrl.zip Edgar Link pending
egrx-20140930.xml Edgar Link completed
egrx-20140930.xsd Edgar Link pending
egrx-20140930_cal.xml Edgar Link unprocessable
egrx-20140930_def.xml Edgar Link unprocessable
egrx-20140930_lab.xml Edgar Link unprocessable
egrx-20140930_pre.xml Edgar Link unprocessable
egrx_q4x2014.htm Edgar Link pending
egrx_q4x2014xchart-48806.jpg Edgar Link pending
exhibit231.htm Edgar Link pending
exhibit311q4.htm Edgar Link pending
exhibit312q4.htm Edgar Link pending
exhibit321q4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending